Are butyrophenones effective for the treatment of primary headache in the emergency department?

Canadian Journal of Emergency Medicine

Volumn 13, Issue 2, 2011, Pages 96-104

  Leong, Lim Beng ^a   Kelly, Anne Maree ^b  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Butyrophenones; Emergency; Migraine

Indexed keywords

BUTYROPHENONE DERIVATIVE; DROPERIDOL; HALOPERIDOL; OLANZAPINE; PETHIDINE; PLACEBO; PROCHLORPERAZINE;

AKATHISIA; ALTERED MENTAL STATUS; ANXIETY; BENIGN HEADACHE; BOLUS INJECTION; DRUG EFFICACY; EMERGENCY TREATMENT; EMERGENCY WARD; EVIDENCE BASED MEDICINE; HEADACHE; HUMAN; MENTAL DISEASE; MIGRAINE; OUTCOMES RESEARCH; PRIMARY HEADACHE; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; EMERGENCY HEALTH SERVICE; TREATMENT OUTCOME;

BUTYROPHENONES; DROPERIDOL; EMERGENCY SERVICE, HOSPITAL; HALOPERIDOL; HEADACHE; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 79960679014     PISSN: 14818035     EISSN: None     Source Type: Journal    
DOI: 10.2310/8000.2011.100301     Document Type: Review

References (26)

1. Vinson DR. Treatment patterns of isolated benign headaches in US emergency departments. Ann Emerg Med 2002; 39:215-22.
2. Silberstein SD, Saper JR, Freitag F. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff's headache and other head pain. 7th ed. New York: Oxford University Press, 2001. p. 121-237.
3. Colman I, Rothney A, Wright SC, et al. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695-700.
4. Friedman BW, Kapoor A, Friedman MS, et al. The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials. Ann Emerg Med 2008;52:705-13.
5. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008;71:1821-8.
6. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache 2004;44: 414-25.
7. Richman PB, Reischel U, Ostrow A, et al. Droperidol for acute migraine headache. Am J Emerg Med 1999;17:398-400.
8. Fisher H. A new approach to emergency department therapy of migraine headache with intravenous haloperidol: a case series. J Emerg Med 1995;13:119-22.
9. Mascia A, Afra J, Schoenen J. Dopamine and migraine: a review of pharmacological, biochemical, neurophysiological, and therapeutic data. Cephalalgia 1998;18:174-82.
10. Trainor A, Miner J. Pain treatment and relief among patients with primary headache subtypes in the ED. Am J Emerg Med 2008;26:1029-34.
11. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
12. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. First edition. Cephalalgia 1991;11:1-12.
13. Honkaniemi J, Liimatainen S, Rainesalo S. Haloperidol in the acute treatment of migraine: a randomized, double blind, placebo controlled study. Headache 2006;46:781-7.
14. Silberstein SD, Young WB, Mendizabal JE, et al. Acute migraine treatment with droperidol: a randomized double blind, placebo controlled trial. Neurology 2003;60:315-21.
15. Richman PB, Allegra J, Eskin B, et al. A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. Am J Emerg Med 2002;20:39-42.
16. Miner JR, Fish SJ, Smith SW, et al. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad Emerg Med 2001;8:873-9.
17. Weaver CS, Jones JB, Chisholm CD, et al. Droperidol vs. prochlorperazine for the treatment of acute headache. J Emerg Med 2004;2:145-50.
18. Hill CH, Miner JR, Martel ML. Olanzapine versus droperidol for the treatment of primary headache in the emergency department. Acad Emerg Med 2008;15:806-11.
19. Kelly AM. Specific pain syndromes: Headache. In: Mace S, Ducharme J, Murphy M, editors. Pain management and sedation: emergency department management. New York: McGraw-Hill, 2006. p. 279-86.
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8:1-96.
21. Jackson CW, Sheehan AH, Reddan JG. Evidence-based review of the black-box warning for droperidol. Am J Health Syst Pharm 2007;64:1174-86.
22. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low dose droperidol administration increase the risk of drug induced QT prolongation and torsades de pointes in the general surgical population? Anesthesiology 2007;107:531-6.
23. Fortney J, Gan T, Graczyk S, et al. A comparison of the efficacy, safety and patient satisfaction of ondansetron versus droperidol as anti-emetics for elective outpatient surgical procedures. S3A-09 and S3A-410 study groups. Anesth Analg 1998;86:731-8.
24. Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high risk inner city emergency department patient population. Acad Emerg Med 2002;9: 1402-10.
25. Dershwitz M. There should be a threshold dose for the FDA black-box warning on droperidol. Anesth Analg 2003;97: 1542-3.
26. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose dependent prolongation of the QT interval. Anesth Analg 1994;79:983-6.